Newland Pharmaceutical's Fondaparinux Sodium API Marketing Application Approved
Stock News
Oct 07
Newland Pharmaceutical Co.,Ltd. (301277.SZ) has announced that it recently received the Chemical Active Pharmaceutical Ingredient Marketing Application Approval Notification for Fondaparinux Sodium API issued by the National Medical Products Administration.
Fondaparinux Sodium is a synthetic selective factor Xa inhibitor with a uniform composition and contains no animal-derived ingredients.
Its indications include the prevention of venous thromboembolism after major orthopedic surgeries such as hip fracture surgery and hip or knee replacement, as well as anticoagulant therapy for deep vein thrombosis, pulmonary embolism, and acute coronary syndrome.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.